Table of Contents Author Guidelines Submit a Manuscript
Neurology Research International
Volume 2010, Article ID 103094, 10 pages
http://dx.doi.org/10.1155/2010/103094
Review Article

Parkinson's Disease: Is It a Toxic Syndrome?

1Toxicology Department, Faculty of Medicine, Mansoura University, Mansoura 35111, Egypt
2Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura 35111, Egypt

Received 8 February 2010; Revised 5 June 2010; Accepted 26 July 2010

Academic Editor: Changiz Geula

Copyright © 2010 Seham A. Gad ELhak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Galvan and T. Wichmann, “Pathophysiology of Parkinsonism,” Clinical Neurophysiology, vol. 119, no. 7, pp. 1459–1474, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Corti, C. Hampe, F. Darios, P. Ibanez, M. Ruberg, and A. Brice, “Parkinson's disease: from causes to mechanisms,” Comptes Rendus, vol. 328, no. 2, pp. 131–142, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Goetz, “Early iconography of Parkinson’s disease,” in Hand Book Of Parkinson's Disease, R. Pahwa and K. Lyons, Eds., pp. 1–18, Informa Healthcare, New York, NY, USA, 4th edition, 2007. View at Google Scholar
  4. K. R. Chaudhuri, D. G. Healy, and A. H. V. Schapira, “Non-motor symptoms of Parkinson's disease: diagnosis and management,” Lancet Neurology, vol. 5, no. 3, pp. 235–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Jankovic and A. E. Lang, “Movement disorders: diagnosis and assessment,” in Neurology in Clinical Practice, W. G. Bradley, R. B. Daroff, G. M. Fenichel, and J. Jankovic, Eds., chapter 24, pp. 293–322, Butterworth-Heinemann (Elsevier), Philadelphia, Pa, USA, 4th edition, 2004. View at Google Scholar
  6. E. G. Gonera, M. van't Hof, H. J. C. Berger, C. Van Weel, and M. W. I. M. Horstink, “Symptoms and duration of the prodromal phase in Parkinson's disease,” Movement Disorders, vol. 12, no. 6, pp. 871–876, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Jankovic, “Pathophysiology and clinical assessment,” in Hand Book of Parkinson's Disease, R. Pahwa and K. Lyons, Eds., pp. 49–67, Informa Healthcare, New York, NY, USA, 4th edition, 2007. View at Google Scholar
  8. R. M. Kelly and P. L. Strick, “Macro-architecture of basal ganglia loops with the cerebral cortex: use of rabies virus to reveal multisynaptic circuits,” Progress in Brain Research, vol. 143, pp. 449–459, 2004. View at Google Scholar · View at Scopus
  9. M. R. DeLong and T. Wichmann, “Circuits and circuit disorders of the basal ganglia,” Archives of Neurology, vol. 64, no. 1, pp. 20–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. D. W. Dickson, “Neuropathology and staging of Parkinson’s disease,” in Parkinson's Disease Genetics and Pathogenesis, T. M. Dawson, Ed., pp. 1–18, Informa Healthcare, New York, NY, USA, 2007. View at Google Scholar
  11. M. S. Pollanen, D. W. Dickson, and C. Bergeron, “Pathology and biology of the Lewy body,” Journal of Neuropathology and Experimental Neurology, vol. 52, no. 3, pp. 183–191, 1993. View at Google Scholar · View at Scopus
  12. H. Braak, E. Braak, D. Yilmazer et al., “Amygdala pathology in Parkinson's disease,” Acta Neuropathologica, vol. 88, no. 6, pp. 493–500, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Braak, D. Sandmann-Keil, U. Rüb et al., “α-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei,” Acta Neuropathologica, vol. 101, no. 3, pp. 195–201, 2001. View at Google Scholar · View at Scopus
  14. E. Kuusisto, L. Parkkinen, and I. Alafuzoff, “Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62,” Journal of Neuropathology and Experimental Neurology, vol. 62, no. 12, pp. 1241–1253, 2003. View at Google Scholar · View at Scopus
  15. K. A. Jellinger and J. Mizuno, “Parkinson’s disease,” in Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, D. W. Dickson, Ed., pp. 159–187, ISN Neuropath Press, Basel, Switzerland, 2003. View at Google Scholar
  16. J. B. Schulz, “Mechanisms of neurodegeneration in idiopathic Parkinson's disease,” Parkinsonism and Related Disorders, vol. 13, no. 3, pp. S306–S308, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. R. G. Perez, J. C. Waymire, E. Lin, J. J. Liu, F. Guo, and M. J. Zigmond, “A role for α-synuclein in the regulation of dopamine biosynthesis,” Journal of Neuroscience, vol. 22, no. 8, pp. 3090–3099, 2002. View at Google Scholar · View at Scopus
  18. A. Sidhu, C. Wersinger, and P. Vernier, “α-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease,” FEBS Letters, vol. 565, no. 1–3, pp. 1–5, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. D. M. Skovronsky, “Tau in Parkinsonian diseases,” in Parkinson's Disease Genetics and Pathogenesis, T. M. Dawson, Ed., pp. 187–198, Informa Healthcare, New York, NY, USA, 2007. View at Google Scholar
  20. T. Ishizawa, P. Mattila, P. Davies, D. Wang, and D. W. Dickson, “Colocalization of tau and alpha-synuclein epitopes in Lewy bodies,” Journal of Neuropathology and Experimental Neurology, vol. 62, no. 4, pp. 389–397, 2003. View at Google Scholar · View at Scopus
  21. M. S. Goldberg, S. M. Fleming, J. J. Palacino et al., “Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons,” Journal of Biological Chemistry, vol. 278, no. 44, pp. 43628–43635, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Zhang, J. Gao, K. K. K. Chung, H. Huang, V. L. Dawson, and T. M. Dawson, “Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 24, pp. 13354–13359, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. B. S. Shastry, “Parkinson disease: etiology, pathogenesis and future of gene therapy,” Neuroscience Research, vol. 41, no. 1, pp. 5–12, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. A. H. Schapira, “Mitochondria in the aetiology and pathogenesis of Parkinson's disease,” The Lancet Neurology, vol. 7, no. 1, pp. 97–109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. J. Chinta and J. K. Andersen, “Redox imbalance in Parkinson's disease,” Biochimica et Biophysica Acta, vol. 1780, no. 11, pp. 1362–1367, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. J. Crocker, P. D. Smith, V. Jackson-Lewis et al., “Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease,” Journal of Neuroscience, vol. 23, no. 10, pp. 4081–4091, 2003. View at Google Scholar · View at Scopus
  27. D. A. Di Monte, “The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?” Lancet Neurology, vol. 2, no. 9, pp. 531–538, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Elbaz and C. Tranchant, “Epidemiologic studies of environmental exposures in Parkinson's disease,” Journal of the Neurological Sciences, vol. 262, no. 1-2, pp. 37–44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. D. A. Di Monte, M. Lavasani, and A. B. Manning-Bog, “Environmental factors in Parkinson's disease,” NeuroToxicology, vol. 23, no. 4-5, pp. 487–502, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. B. K. Barlow, D. A. Cory-Slechta, E. K. Richfield, and M. Thiruchelvam, “The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder,” Reproductive Toxicology, vol. 23, no. 3, pp. 457–470, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. C. H. Tsai, S. K. Lo, L. C. See et al., “Environmental risk factors of young onset Parkinson's disease: a case-control study,” Clinical Neurology and Neurosurgery, vol. 104, no. 4, pp. 328–333, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. T. P. Brown, P. C. Rumsby, A. C. Capleton, L. Rushton, and L. S. Levy, “Pesticides and Parkinson's disease—is there a link?” Environmental Health Perspectives, vol. 114, no. 2, pp. 156–164, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. J. M. Hatcher, K. D. Pennell, and G. W. Miller, “Parkinson's disease and pesticides: a toxicological perspective,” Trends in Pharmacological Sciences, vol. 29, no. 6, pp. 322–329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. C. D. Klaassen, Ed., Casarett & Doull’s Toxicology: The Basic Science of Poisons, McGraw-Hill, Boston, Mass, USA, 2001.
  35. L. J. Chapman, S. L. Sauter, R. A. Henning, R. L. Levine, C. G. Matthews, and H. A. Peters, “Finger tremor after carbon disulfide-based pesticide exposures,” Archives of Neurology, vol. 48, no. 8, pp. 866–870, 1991. View at Google Scholar · View at Scopus
  36. M. Thiruchelvam, E. K. Richfield, R. B. Baggs, A. W. Tank, and D. A. Cory-Slechta, “The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease,” Journal of Neuroscience, vol. 20, no. 24, pp. 9207–9214, 2000. View at Google Scholar · View at Scopus
  37. M. Thiruchelvam, B. J. Brockel, E. K. Richfield, R. B. Baggs, and D. A. Cory-Slechta, “Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?” Brain Research, vol. 873, no. 2, pp. 225–234, 2000. View at Publisher · View at Google Scholar · View at Scopus
  38. A. L. McCormack, M. Thiruchelvam, A. B. Manning-Bog et al., “Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat,” Neurobiology of Disease, vol. 10, no. 2, pp. 119–127, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Peng, F. F. Stevenson, S. R. Doctrow, and J. K. Andersen, “Superoxide dismutase/catalase mimetics are neuroprotective against selective paraquat-mediated dopaminergic neuron death in the substantial Nigra: implications for Parkinson disease,” Journal of Biological Chemistry, vol. 280, no. 32, pp. 29194–29198, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. X. Li, J. Yin, C.-M. Cheng, J.-L. Sun, Z. Li, and Y.-L. Wu, “Paraquat induces selective dopaminergic nigrostriatal degeneration in aging C57BL/6 mice,” Chinese Medical Journal, vol. 118, no. 16, pp. 1357–1361, 2005. View at Google Scholar · View at Scopus
  41. K. Kuter, M. Śmiałowska, J. Wierońska et al., “Toxic influence of subchronic paraquat administration on dopaminergic neurons in rats,” Brain Research, vol. 1155, no. 1, pp. 196–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. V. N. Uversky, “Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration,” Cell and Tissue Research, vol. 318, no. 1, pp. 225–241, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. J. R. Richardson, Y. Quan, T. B. Sherer, J. T. Greenamyre, and G. W. Miller, “Paraquat neurotoxicity is distinct from that of MPTP and rotenone,” Toxicological Sciences, vol. 88, no. 1, pp. 193–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Ramachandiran, J. M. Hansen, D. P. Jones, J. R. Richardson, and G. W. Miller, “Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation,” Toxicological Sciences, vol. 95, no. 1, pp. 163–171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. G. W. Miller, “Paraquat: the red herring of Parkinson's disease research,” Toxicological Sciences, vol. 100, no. 1, pp. 1–2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. D. A. Cory-slechta, M. Thiruchelvam, and D. A. Di Monte, “Letter regarding: “Paraquat: the red herring of parkinson's disease research”,” Toxicological Sciences, vol. 103, no. 1, pp. 215–216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. G. W. Miller, “Paraquat and parkinson's disease: response by Dr. Miller, Part II,” Toxicological Sciences, vol. 103, no. 1, pp. 222–223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. R. M. LoPachin and T. Gavin, “Response to “Paraquat: the red herring of Parkinson's disease research”,” Toxicological sciences, vol. 103, no. 1, pp. 219–221, 2008. View at Google Scholar
  49. K. Prasad, E. Tarasewicz, J. Mathew et al., “Toxicokinetics and toxicodynamics of paraquat accumulation in mouse brain,” Experimental Neurology, vol. 215, no. 2, pp. 358–367, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. H. Bhatt, M. A. Elias, and A. K. Mankodi, “Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases,” Neurology, vol. 52, no. 7, pp. 1467–1471, 1999. View at Google Scholar · View at Scopus
  51. D. B. Hancock, E. R. Martin, G. M. Mayhew et al., “Pesticide exposure and risk of Parkinson's disease: a family-based case-control study,” BMC Neurology, vol. 8, article 6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. D. J. Karen, W. Li, P. R. Harp, J. S. Gillette, and J. R. Bloomquist, “Striatal dopaminergic pathways as a target tor the insecticides permethrin and chlorpyrifos,” NeuroToxicology, vol. 22, no. 6, pp. 811–817, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Betarbet, R. M. Canet-Aviles, T. B. Sherer et al., “Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, α-synuclein, and the ubiquitin-proteasome system,” Neurobiology of Disease, vol. 22, no. 2, pp. 404–420, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Shimohama, H. Sawada, Y. Kitamura, and T. Taniguchi, “Disease model: Parkinson's disease,” Trends in Molecular Medicine, vol. 9, no. 8, pp. 360–365, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. P. Caboni, T. B. Sherer, N. Zhang et al., “Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease,” Chemical Research in Toxicology, vol. 17, no. 11, pp. 1540–1548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. J. R. Cannon, V. Tapias, H. M. Na, A. S. Honick, R. E. Drolet, and J. T. Greenamyre, “A highly reproducible rotenone model of Parkinson's disease,” Neurobiology of Disease, vol. 34, no. 2, pp. 279–290, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Takeuchi, T. Yanagida, M. Inden et al., “Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models,” Journal of Neuroscience Research, vol. 87, no. 2, pp. 576–585, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. B. Monti, V. Gatta, F. Piretti, S. S. Raffaelli, M. Virgili, and A. Contestabile, “Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of α-synuclein,” Neurotoxicity Research, vol. 17, no. 2, pp. 130–141, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. T. M. Dawson, A. S. Mandir, and M. K. Lee, “Animal models of PD: pieces of the same puzzle?” Neuron, vol. 35, no. 2, pp. 219–222, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. A. G. Kanthasamy, M. Kitazawa, A. Kanthasamy, and V. Anantharam, “Dieldrin-induced neurotoxicity: relevance to Parkinson's disease pathogenesis,” NeuroToxicology, vol. 26, no. 4, pp. 701–719, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. G. W. Miller, J. D. Erickson, J. T. Perez et al., “Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease,” Experimental Neurology, vol. 156, no. 1, pp. 138–148, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Sanchez-Ramos, A. Facca, A. Basit, and S. Song, “Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures,” Experimental Neurology, vol. 150, no. 2, pp. 263–271, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. H. S. Chun, G. E. Gibson, L. A. DeGiorgio, H. Zhang, V. J. Kidd, and J. H. Son, “Dopaminergic cell death induced by MPP+, oxidant and specific neurotoxicants shares the common molecular mechanism,” Journal of Neurochemistry, vol. 76, no. 4, pp. 1010–1021, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. K. Kannan, R. F. Holcombe, S. K. Jain et al., “Evidence for the induction of apoptosis by endosulfan in a human T-cell leukemic line,” Molecular and Cellular Biochemistry, vol. 205, no. 1-2, pp. 53–66, 2000. View at Google Scholar · View at Scopus
  65. L. Annunziato, S. Amoroso, A. Pannaccione et al., “Apoptosis induced in neuronal cells by oxidative stress: role played by caspases and intracellular calcium ions,” Toxicology Letters, vol. 139, no. 2-3, pp. 125–133, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. V. Anantharam, M. Kitazawa, J. Wagner, S. Kaul, and A. G. Kanthasamy, “Caspase-3-dependent proteolytic cleavage of protein kinase Cδ is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl,” Journal of Neuroscience, vol. 22, no. 5, pp. 1738–1751, 2002. View at Google Scholar · View at Scopus
  67. A. G. Kanthasamy, M. Kitazawa, A. Kanthasamy, and V. Anantharam, “Role of proteolytic activation of protein kinase Cδ in oxidative stress-induced apoptosis,” Antioxidants and Redox Signaling, vol. 5, no. 5, pp. 609–620, 2003. View at Google Scholar · View at Scopus
  68. A. G. Kanthasamy, M. Kitazawa, S. Kaul et al., “Proteolytic activation of proapoptotic kinase PKCδ is regulated by overexpression of Bcl-2: implications for oxidative stress and environmental factors in Parkinson's disease,” Annals of the New York Academy of Sciences, vol. 1010, pp. 683–686, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Kaul, A. Kanthasamy, M. Kitazawa, V. Anantharam, and A. G. Kanthasamy, “Caspase-3 dependent proteolytic activation of protein kinase Cδ mediates and regulates 1-methyl-4-phenylpyridinium (MPP+)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration,” European Journal of Neuroscience, vol. 18, no. 6, pp. 1387–1401, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Kitazawa, V. Anantharam, and A. G. Kanthasamy, “Dieldrin induces apoptosis by promoting caspase-3-dependent proteolytic cleavage of protein kinase Cδ in dopaminergic cells: relevance to oxidative stress and dopaminergic degeneration,” Neuroscience, vol. 119, no. 4, pp. 945–964, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Kitazawa, V. Anantharam, A. Kanthasamy, and A. G. Kanthasamy, “Dieldrin promotes proteolytic cleavage of poly(ADP-ribose) polymerase and apoptosis in dopaminergic cells: protective effect of mitochondrial anti-apoptotic protein Bcl-2,” NeuroToxicology, vol. 25, no. 4, pp. 589–598, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. F. Sun, V. Anantharam, and A. G. Kanthasamy, “Dieldrin exposure impairs the ubiquitin-proteosome function and promotes-synuclein aggregation in mesencephalic dopaminergic neuronal cells: relevance of environmental factors in the etiopathogenesis of Parkinson’s disease,” Toxicologist, vol. 78, p. 621, 2004. View at Google Scholar
  73. M. L. Kirby, K. Castagnoli, and J. R. Bloomquist, “In vivo effects of deltamethrin on dopamine neurochemistry and the role of augmented neurotransmitter release,” Pesticide Biochemistry and Physiology, vol. 65, no. 3, pp. 160–168, 1999. View at Publisher · View at Google Scholar · View at Scopus
  74. D. J. Karen, W. Li, P. R. Harp, J. S. Gillette, and J. R. Bloomquist, “Striatal dopaminergic pathways as a target tor the insecticides permethrin and chlorpyrifos,” NeuroToxicology, vol. 22, no. 6, pp. 811–817, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. J. S. Gillette and J. R. Bloomquist, “Differential up-regulation of striatal dopamine transporter and α-synuclein by the pyrethroid insecticide permethrin,” Toxicology and Applied Pharmacology, vol. 192, no. 3, pp. 287–293, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. I. V. Tabarean and T. Narahashi, “Kinetics of modulation of tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels by tetramethrin and deltamethrin,” Journal of Pharmacology and Experimental Therapeutics, vol. 299, no. 3, pp. 988–997, 2001. View at Google Scholar · View at Scopus
  77. M. A. Elwan, J. R. Richardson, T. S. Guillot, W. M. Caudle, and G. W. Miller, “Pyrethroid pesticide-induced alterations in dopamine transporter function,” Toxicology and Applied Pharmacology, vol. 211, no. 3, pp. 188–197, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. K. J. Barnham and A. I. Bush, “Metals in Alzheimer's and Parkinson's diseases,” Current Opinion in Chemical Biology, vol. 12, no. 2, pp. 222–228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. M. A. Collins and E. J. Neafsey, “Potential neurotoxic “agents provocateurs” in Parkinson's disease,” Neurotoxicology and Teratology, vol. 24, no. 5, pp. 571–577, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Quintanar, “Manganese neurotoxicity: a bioinorganic chemist's perspective,” Inorganica Chimica Acta, vol. 361, no. 4, pp. 875–884, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. V. N. Uversky, J. Li, K. Bower, and A. L. Fink, “Synergistic effects of pesticides and metals on the fibrillation of α-synuclein: implications for Parkinson's disease,” NeuroToxicology, vol. 23, no. 4-5, pp. 527–536, 2002. View at Publisher · View at Google Scholar · View at Scopus
  82. L. Iacovelli, F. Fulceri, A. De Blasi, F. Nicoletti, S. Ruggieri, and F. Fornai, “The neurotoxicity of amphetamines: bridging drugs of abuse and neurodegenerative disorders,” Experimental Neurology, vol. 201, no. 1, pp. 24–31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. T. R. Guilarte, “Is methamphetamine abuse a risk factor in parkinsonism?” Neurotoxicology, vol. 22, pp. 725–731, 2001. View at Google Scholar
  84. J. L. Tillerson and G. W. Miller, “Grid performance test to measure behavioral impairment in the MPTP-treated-mouse model of parkinsonism,” Journal of Neuroscience Methods, vol. 123, no. 2, pp. 189–200, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. R. Haobam, K. M. Sindhu, G. Chandra, and K. P. Mohanakumar, “Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains,” Behavioural Brain Research, vol. 163, no. 2, pp. 159–167, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. E. Petroske, G. E. Meredith, S. Callen, S. Totterdell, and Y. S. Lau, “Mouse model of parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment,” Neuroscience, vol. 106, pp. 589–601, 2001. View at Google Scholar
  87. P. A. Serra, S. Pluchino, B. Marchetti, M. S. Desole, and E. Miele, “The MPTP mouse model: cues on DA release and neural stem cell restorative role,” Parkinsonism and Related Disorders, vol. 14, pp. S189–S193, 2008. View at Google Scholar
  88. X. J. He, H. Yamauchi, K. Uetsuka, and H. Nakayama, “Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson's disease,” NeuroToxicology, vol. 29, no. 3, pp. 413–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. G. E. Meredith, S. Totterdell, J. A. Potashkin, and D. J. Surmeier, “Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol,” Parkinsonism and Related Disorders, vol. 14, no. 2, pp. S112–S115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Schober, “Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP,” Cell and Tissue Research, vol. 318, no. 1, pp. 215–224, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. S. T. Kim, H. J. Son, J. H. Choi, I. J. Ji, and O. Hwang, “Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease,” Brain Research, vol. 1306, pp. 176–183, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. L. P. Quinn, T. O. Stean, H. Chapman et al., “Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration,” Journal of Neuroscience Methods, vol. 156, no. 1-2, pp. 218–227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Sedelis, K. Hofele, G. W. Auburger, S. Morgan, J. P. Huston, and K. W. R. Schwarting, “MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences,” Behavior Genetics, vol. 30, no. 3, pp. 171–182, 2000. View at Google Scholar
  94. Y. Yasuda, T. Shimoda, K. Uno et al., “The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains,” Journal of Neuroimmunology, vol. 204, no. 1, pp. 43–51, 2008. View at Publisher · View at Google Scholar
  95. S. C. Hu, F. W. Chang, Y. J. Sung, W. M. Hsu, and E. H. Lee, “Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the substantia nigra and the locus coeruleus in BALB/c mice,” The Journal of Pharmacology and Experimental Therapeutics, vol. 259, no. 3, pp. 1379–1387, 1991. View at Google Scholar
  96. M. W. Jakowec and G. M. Petzinger, “1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates,” Comparative Medicine, vol. 54, no. 5, pp. 497–513, 2004. View at Google Scholar · View at Scopus
  97. A. Elbaz and C. Tranchant, “Epidemiologic studies of environmental exposures in Parkinson's disease,” Journal of the Neurological Sciences, vol. 262, no. 1-2, pp. 37–44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. F. Fornai, “Novel Therapeutic Target in PD: Experimental Models,” in Advances in Alzheimer’s and Parkinson’s Disease, A. Fisher, Ed., vol. 57, pp. 57–73, Springer, NY, USA, 2008. View at Publisher · View at Google Scholar
  99. E. Lane and S. Dunnett, “Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?” Psychopharmacology, vol. 199, no. 3, pp. 303–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. A. B. Manning-Bog and J. W. Langston, “Model fusion: the next phase in developing animal models for Parkinson's disease,” Neurotoxicity Research, vol. 11, no. 3-4, pp. 219–240, 2007. View at Publisher · View at Google Scholar · View at Scopus